Franco-Brazilian collaboration on 'emerging diseases' research

29 July 2019

The Pasteur Institute, a French foundation for research on infectious disease prevention and treatment, inaugurated the Scientific Pasteur-USP Platform at the University of São Paulo (USP), Brazil, this month.

The platform is the result of a scientific partnership between the Pasteur Institute, the USP and Brazil’s Oswaldo Cruz Foundation (Fiocruz) signed in June 2015.

This platform will develop research to study emerging pathogens, of which infections can cause damage to the central nervous system, such as the Zika, Dengue, Yellow fever and Influenza viruses, as well as protozoa such as the trypanosomes that cause the sleeping sickness. The main goal is to develop methods to prevent epidemics of these diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK